SK49999A3 - Oxadiazole derivatives, process for their preparation and their use as medicaments - Google Patents

Oxadiazole derivatives, process for their preparation and their use as medicaments Download PDF

Info

Publication number
SK49999A3
SK49999A3 SK499-99A SK49999A SK49999A3 SK 49999 A3 SK49999 A3 SK 49999A3 SK 49999 A SK49999 A SK 49999A SK 49999 A3 SK49999 A3 SK 49999A3
Authority
SK
Slovakia
Prior art keywords
formula
phenyl
substituted
radical
alkyl
Prior art date
Application number
SK499-99A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Brenner
Roland Maier
Marion Wienrich
Thomas Weiser
Rainer Palluk
Wolf-Dietrich Bechtel
Angelo Sagrada
Helmut Ensinger
Uwe Pschorn
Raffaele Cesana
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of SK49999A3 publication Critical patent/SK49999A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK499-99A 1996-10-18 1997-10-15 Oxadiazole derivatives, process for their preparation and their use as medicaments SK49999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19643037A DE19643037A1 (de) 1996-10-18 1996-10-18 Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP1997/005693 WO1998017652A1 (de) 1996-10-18 1997-10-15 Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
SK49999A3 true SK49999A3 (en) 1999-11-08

Family

ID=7809114

Family Applications (1)

Application Number Title Priority Date Filing Date
SK499-99A SK49999A3 (en) 1996-10-18 1997-10-15 Oxadiazole derivatives, process for their preparation and their use as medicaments

Country Status (32)

Country Link
US (1) US6277872B1 (hu)
EP (1) EP0934288B1 (hu)
JP (1) JP3333523B2 (hu)
KR (1) KR20000049253A (hu)
CN (1) CN1086698C (hu)
AR (1) AR008496A1 (hu)
AT (1) ATE315034T1 (hu)
AU (1) AU737552B2 (hu)
BG (1) BG103251A (hu)
BR (1) BR9714354A (hu)
CA (1) CA2268954C (hu)
CO (1) CO4920253A1 (hu)
CZ (1) CZ138099A3 (hu)
DE (2) DE19643037A1 (hu)
EE (1) EE9900147A (hu)
ES (1) ES2256880T3 (hu)
HK (1) HK1020956A1 (hu)
HR (1) HRP970553A2 (hu)
HU (1) HUP0001652A3 (hu)
ID (1) ID18613A (hu)
IL (1) IL129315A0 (hu)
NO (1) NO312512B1 (hu)
NZ (1) NZ335598A (hu)
PE (1) PE11199A1 (hu)
PL (1) PL332432A1 (hu)
RU (1) RU2182905C2 (hu)
SK (1) SK49999A3 (hu)
TR (1) TR199900848T2 (hu)
TW (1) TW413678B (hu)
WO (1) WO1998017652A1 (hu)
YU (1) YU40997A (hu)
ZA (1) ZA979220B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IT1300056B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
TWI258472B (en) 1999-02-15 2006-07-21 Eisai Co Ltd Heterodiazinone derivatives
PT1070708E (pt) 1999-07-21 2004-05-31 Hoffmann La Roche Derivados de triazol
EP1582519A3 (en) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
US20030225081A1 (en) * 2000-09-18 2003-12-04 Satoshi Nagato Pyridazinones and triazinones and medicinal use thereof
MXPA03007513A (es) * 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
WO2003029210A2 (en) * 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
NZ537980A (en) 2002-08-23 2007-08-31 Rigel Pharmaceuticals Inc Pyridyl substituted heterocycles useful for treating or preventing HCV infection
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2006109876A1 (ja) * 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. 不随意運動治療剤
CN101203498A (zh) 2005-05-02 2008-06-18 里格尔药品股份有限公司 包括可代谢部分的杂环抗病毒化合物及其用途
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CN104478821B (zh) * 2007-10-04 2016-09-28 默克雪兰诺有限公司 噁二唑二芳基化合物
US9045442B2 (en) * 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
RU2531915C2 (ru) 2008-06-09 2014-10-27 Людвиг-Максимилианс-Универзитет Мюнхен Новые лекарственные средства для ингибирования агрегации белков, вовлеченных в заболевания, связанные с агрегацией белков, и нейродегенеративные заболевания
US9095596B2 (en) * 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
BR112015003824B1 (pt) * 2012-08-24 2022-10-04 Treventis Corporation Composto, composição farmacêutica e uso do composto
DK3110812T3 (da) 2014-02-27 2019-07-08 Treventis Corp Anti-amyloidforbindelser indeholdende benzofurazan
EP3135114B1 (en) 2014-04-24 2019-03-20 Sumitomo Chemical Company, Limited Diaryl-azole compound
KR20170113529A (ko) * 2014-09-25 2017-10-12 유니버시티 오브 노트르 담 듀락 비-베타 락탐 항생제
CN107286174B (zh) * 2016-04-11 2020-08-18 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
WO2018049404A1 (en) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Compounds for the treatment of clostridium difficile infection
CA3062749A1 (en) 2017-05-12 2018-11-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compounds for use in the treatment or prevention of melanoma
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
EP4403185A1 (en) 2021-09-15 2024-07-24 University of The Ryukyus Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
WO2023042887A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物
EP4173485A1 (en) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
JPS52272A (en) * 1975-10-17 1977-01-05 Takeda Chem Ind Ltd Process for preparing 1,2,4-oxadiazole derivatives
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
EP0276432A3 (de) * 1986-12-12 1988-10-26 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
JPH02250873A (ja) * 1989-03-24 1990-10-08 Mitsubishi Petrochem Co Ltd １，２，４―オキサジアゾール誘導体及びそれを有効成分とする除草剤
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
EP0596933A1 (en) * 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
DE4401107A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 3-Aryl-alkenyl-1,2,4-oxadiazol-Derivate
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest

Also Published As

Publication number Publication date
HK1020956A1 (en) 2000-05-26
BG103251A (en) 2000-02-29
ID18613A (id) 1998-04-23
US6277872B1 (en) 2001-08-21
CA2268954A1 (en) 1998-04-30
YU40997A (sh) 2000-10-30
JP2000505089A (ja) 2000-04-25
DE59712543D1 (de) 2006-03-30
KR20000049253A (ko) 2000-07-25
NO312512B1 (no) 2002-05-21
CO4920253A1 (es) 2000-05-29
AR008496A1 (es) 2000-01-19
HRP970553A2 (en) 1998-08-31
PL332432A1 (en) 1999-09-13
JP3333523B2 (ja) 2002-10-15
EP0934288A1 (de) 1999-08-11
AU737552B2 (en) 2001-08-23
BR9714354A (pt) 2000-04-11
HUP0001652A3 (en) 2002-12-28
ZA979220B (en) 1998-04-20
CN1233245A (zh) 1999-10-27
CN1086698C (zh) 2002-06-26
CA2268954C (en) 2006-06-13
IL129315A0 (en) 2000-02-17
DE19643037A1 (de) 1998-04-23
CZ138099A3 (cs) 1999-11-17
AU4867697A (en) 1998-05-15
RU2182905C2 (ru) 2002-05-27
NZ335598A (en) 2001-06-29
EP0934288B1 (de) 2006-01-04
WO1998017652A1 (de) 1998-04-30
HUP0001652A2 (hu) 2001-01-29
NO991815L (no) 1999-04-16
ES2256880T3 (es) 2006-07-16
ATE315034T1 (de) 2006-02-15
PE11199A1 (es) 1999-03-03
TW413678B (en) 2000-12-01
EE9900147A (et) 1999-12-15
NO991815D0 (no) 1999-04-16
TR199900848T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
SK49999A3 (en) Oxadiazole derivatives, process for their preparation and their use as medicaments
Burbuliene et al. Synthesis and anti-inflammatory activity of derivatives of 5-[(2-disubstitutedamino-6-methyl-pyrimidin-4-yl)-sulfanylmethyl]-3H-1, 3, 4-oxadiazole-2-thiones
US4716164A (en) As-triazinones
US20040235877A1 (en) Novel use of tricyclic compound
JP2004521908A (ja) Ｍｍｐ阻害剤としてのトリアゾロ化合物
CN107427506A (zh) 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
MX2011007991A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su uso en terapeutica.
JPH05155887A (ja) アゾール誘導体
BR112019020278A2 (pt) Composto, e, composição farmacêutica
JP4757382B2 (ja) 神経保護作用を有するトリアゾロン
JPH11513376A (ja) 選択的β▲下３▼−アドレナリン作動剤
CN102724975A (zh) IRE-1α抑制剂
JP4589531B2 (ja) 新規ジフェニル置換５員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用
NO840329L (no) Fremgangsmaate for fremstilling av 4-cyanopyridazin-derivater.
JP3086692B2 (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
US4925845A (en) 2 heteroaryl 3,3 dialkyl-5-(3 oxo-2,3,4,5 tetrahydro-6 pyridazinyl)-3H-indoles
CN102558167A (zh) Gk和ppar双重激动活性的噻唑烷二酮衍生物
CA3022195C (en) Compounds for modulating aquaporins
ES2876285T3 (es) Derivados de acetamida de 2-(1,2,4-triazol-3-ilsulfanil)-N-1,3,4-tiadiazol-2-ilo que son útiles para el tratamiento de la diabetes
RU2259371C2 (ru) Замещенные 5r1,6r2 1,3,4-тиадиазин-2 амины и содержащие их фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулянтным и антиагрегантным действием
NO811667L (no) Fremgangsmaate ved fremstilling av substituerte pyrazinyl-1,2,4-oxadiazoler
HU197003B (en) Process for producing new isoxazole derivatives and pharmaceuticals comprising same
JP2002512232A (ja) 新規ジフェニル置換６員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用
USRE33125E (en) 3- and 5-[3-(1-arylureido)]-1,2,4-triazoles
JPH0219111B2 (hu)